Last reviewed · How we verify
Investigational Influenza Vaccine 2
Investigational Influenza Vaccine 2 is a Biologic drug developed by ModernaTX, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Investigational Influenza Vaccine 2 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test (NA)
- Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults (PHASE1)
- A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults (PHASE1, PHASE2)
- Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational Influenza Vaccine 2 CI brief — competitive landscape report
- Investigational Influenza Vaccine 2 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI
Frequently asked questions about Investigational Influenza Vaccine 2
What is Investigational Influenza Vaccine 2?
Investigational Influenza Vaccine 2 is a Biologic drug developed by ModernaTX, Inc..
Who makes Investigational Influenza Vaccine 2?
Investigational Influenza Vaccine 2 is developed by ModernaTX, Inc. (see full ModernaTX, Inc. pipeline at /company/modernatx-inc).
What development phase is Investigational Influenza Vaccine 2 in?
Investigational Influenza Vaccine 2 is in Phase 1.